Javid J. Moslehi

42.0k total citations · 13 hit papers
211 papers, 16.0k citations indexed

About

Javid J. Moslehi is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Javid J. Moslehi has authored 211 papers receiving a total of 16.0k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Cardiology and Cardiovascular Medicine, 93 papers in Oncology and 52 papers in Molecular Biology. Recurrent topics in Javid J. Moslehi's work include Chemotherapy-induced cardiotoxicity and mitigation (57 papers), Cancer Immunotherapy and Biomarkers (40 papers) and CAR-T cell therapy research (24 papers). Javid J. Moslehi is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (57 papers), Cancer Immunotherapy and Biomarkers (40 papers) and CAR-T cell therapy research (24 papers). Javid J. Moslehi collaborates with scholars based in United States, France and Italy. Javid J. Moslehi's co-authors include Douglas B. Johnson, Joe‐Elie Salem, Justin M. Balko, Bénédicte Lebrun‐Vignes, Michael W. Deininger, Caroline A. Nebhan, John D. Groarke, Ali Manouchehri, William G. Kaelin and Douglas B. Johnson and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Javid J. Moslehi

201 papers receiving 15.8k citations

Hit Papers

Declining NAD+ Induces a Pseudohypoxic State Disrupting N... 2013 2026 2017 2021 2013 2018 2018 2022 2020 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging
    2013 1.1k citations Javid J. Moslehi et al. profile →
  2. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
    2018 1.1k citations Anju Nohria, Kerry L. Reynolds et al. profile →
  3. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
    2018 836 citations Joe‐Elie Salem, Ali Manouchehri et al. The Lancet Oncology profile →
  4. Immune-checkpoint inhibitors: long-term implications of toxicity
    2022 610 citations Douglas B. Johnson, Javid J. Moslehi et al. Nature Reviews Clinical Oncology profile →
  5. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy
    2020 440 citations Javid J. Moslehi et al. profile →
  6. Cardiovascular Toxic Effects of Targeted Cancer Therapies
    2016 428 citations Javid J. Moslehi profile →
  7. Immune checkpoint inhibitors and cardiovascular toxicity
    2018 390 citations Javid J. Moslehi et al. The Lancet Oncology profile →
  8. Recognition and Initial Management of Fulminant Myocarditis
    2020 360 citations Javid J. Moslehi, Ravi V. Shah et al. Circulation profile →
  9. Cardiovascular toxicities associated with immune checkpoint inhibitors
    2019 342 citations Jarushka Naidoo, Robert F. Padera et al. profile →
  10. Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
    2015 319 citations Javid J. Moslehi et al. Journal of Clinical Oncology profile →
  11. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
    2019 260 citations Douglas B. Johnson, Ali Manouchehri et al. Journal for ImmunoTherapy of Cancer profile →
  12. Diagnosis and Treatment of Acute Myocarditis
    2023 152 citations Javid J. Moslehi et al. profile →
  13. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective
    2024 67 citations Paul Gougis, Floriane Jochum et al. EClinicalMedicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Javid J. Moslehi United States 68 6.6k 6.4k 3.7k 2.2k 1.8k 211 16.0k
Thomas Force United States 67 3.2k 0.5× 6.5k 1.0× 8.9k 2.4× 1.4k 0.6× 947 0.5× 158 16.8k
Meinrad Gawaz Germany 82 3.2k 0.5× 11.6k 1.8× 5.5k 1.5× 2.8k 1.3× 4.2k 2.4× 607 26.7k
Jourik A. Gietema Netherlands 56 3.5k 0.5× 2.1k 0.3× 3.0k 0.8× 2.1k 0.9× 424 0.2× 252 10.1k
Christoph Röcken Germany 71 5.3k 0.8× 1.6k 0.2× 8.2k 2.2× 2.2k 1.0× 1.6k 0.9× 474 17.2k
Sandra M. Swain United States 66 15.4k 2.3× 3.3k 0.5× 5.1k 1.4× 4.8k 2.2× 971 0.6× 337 23.4k
Agneta Siegbahn Sweden 58 1.0k 0.2× 5.9k 0.9× 3.5k 1.0× 974 0.4× 2.2k 1.3× 191 14.0k
Stefan Sleijfer Netherlands 61 7.1k 1.1× 1.1k 0.2× 4.2k 1.1× 4.7k 2.1× 1.5k 0.8× 379 13.6k
Gian Paolo Fadini Italy 65 2.4k 0.4× 1.9k 0.3× 6.5k 1.8× 1.3k 0.6× 1.9k 1.1× 323 14.9k
Hans Wildiers Belgium 54 7.5k 1.1× 1.0k 0.2× 2.7k 0.7× 3.3k 1.5× 771 0.4× 390 14.6k
Daniel I. Simon United States 63 1.0k 0.2× 3.8k 0.6× 4.3k 1.2× 1.9k 0.9× 3.0k 1.7× 197 15.2k

Countries citing papers authored by Javid J. Moslehi

Since Specialization
Citations

This map shows the geographic impact of Javid J. Moslehi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javid J. Moslehi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javid J. Moslehi more than expected).

Fields of papers citing papers by Javid J. Moslehi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javid J. Moslehi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javid J. Moslehi. The network helps show where Javid J. Moslehi may publish in the future.

Co-authorship network of co-authors of Javid J. Moslehi

This figure shows the co-authorship network connecting the top 25 collaborators of Javid J. Moslehi. A scholar is included among the top collaborators of Javid J. Moslehi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javid J. Moslehi. Javid J. Moslehi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baylis, Richard A., Lei Hou, Justin M. Balko, et al.. (2026). CXCR6 + T Cells Drive Immune Checkpoint Inhibitor Myocarditis. Circulation. 153(10). 754–768. 1 indexed citations
2.
Lai, Carol, Petros Grivas, Shailender Bhatia, et al.. (2025). Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report. European Heart Journal - Case Reports. 9(2). ytaf019–ytaf019. 5 indexed citations
3.
Chen, Yen‐Chou, et al.. (2025). Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review. Critical Reviews in Oncology/Hematology. 215. 104877–104877.
4.
Gougis, Paul, Floriane Jochum, Baptiste Abbar, et al.. (2024). Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective. EClinicalMedicine. 70. 102536–102536. 67 indexed citations breakdown →
5.
Amancherla, Kaushik, Kelly Schlendorf, Caitlyn Vlasschaert, et al.. (2023). Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multicenter study. American Journal of Transplantation. 23(8). 1256–1263. 10 indexed citations
6.
7.
Naidoo, Jarushka, Catherine J. Murphy, Michael B. Atkins, et al.. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. Journal for ImmunoTherapy of Cancer. 11(3). e006398–e006398. 73 indexed citations
8.
Jing, Ying, Jingwen Yang, Douglas B. Johnson, Javid J. Moslehi, & Leng Han. (2022). Harnessing big data to characterize immune-related adverse events. Nature Reviews Clinical Oncology. 19(4). 269–280. 83 indexed citations
9.
Boughdad, Sarah, Sofiya Latifyan, Craig Fenwick, et al.. (2021). 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. Journal for ImmunoTherapy of Cancer. 9(10). e003594–e003594. 49 indexed citations
10.
11.
Moslehi, Javid J., Andrew H. Lichtman, Arlene H. Sharpe, Lorenzo Galluzzi, & Richard N. Kitsis. (2021). Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms. Journal of Clinical Investigation. 131(5). 137 indexed citations
12.
Allenbach, Yves, C. Anquetil, Ali Manouchehri, et al.. (2020). Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmunity Reviews. 19(8). 102586–102586. 96 indexed citations
13.
Song, Haocan, Fei Ye, Javid J. Moslehi, et al.. (2020). Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy. Cancer Immunology Research. 8(7). 851–855. 42 indexed citations
14.
Johnson, Douglas B., Kerry L. Reynolds, Ryan J. Sullivan, et al.. (2020). Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. The Lancet Oncology. 21(8). e398–e404. 78 indexed citations
15.
Balko, Justin M., et al.. (2020). Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. British Journal of Clinical Pharmacology. 86(9). 1778–1789. 45 indexed citations
16.
Johnson, Douglas B., Ali Manouchehri, Alexandra M. Haugh, et al.. (2019). Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. Journal for ImmunoTherapy of Cancer. 7(1). 134–134. 260 indexed citations breakdown →
17.
Grouthier, Virginie, Bénédicte Lebrun‐Vignes, Andrew M. Glazer, et al.. (2018). Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart. 104(22). 1859–1863. 40 indexed citations
18.
Groarke, John D., Dan Tong, Jay Khambhati, Susan Cheng, & Javid J. Moslehi. (2012). Breast Cancer Therapies and Cardiomyopathy. Medical Clinics of North America. 96(5). 1001–1019. 10 indexed citations
19.
Moslehi, Javid J., Yoji Andrew Minamishima, Jianru Shi, et al.. (2010). Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy. Circulation. 122(10). 1004–1016. 138 indexed citations
20.
Peng, Stanford L., Javid J. Moslehi, Marie Robert, & Joe Craft. (1998). Perforin Protects Against Autoimmunity in Lupus-Prone Mice. The Journal of Immunology. 160(2). 652–660. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Force Breakdown of academic impact, for papers by Meinrad Gawaz Breakdown of academic impact, for papers by Jourik A. Gietema Breakdown of academic impact, for papers by Christoph Röcken Breakdown of academic impact, for papers by Sandra M. Swain Breakdown of academic impact, for papers by Agneta Siegbahn Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Gian Paolo Fadini Breakdown of academic impact, for papers by Hans Wildiers Breakdown of academic impact, for papers by Daniel I. Simon
Rankless by CCL
2026